Yuzuru Niibe1, Hideomi Yamashita2, Kenji Sekiguchi3, Wataru Takahashi2, Kenshiro Shiraishi2, Kae Okuma2, Atsuro Terahara4, Jiro Kawamori3, Keiichi Nakagawa2. 1. Department of Radiology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan Department of Radiation Oncology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan yniibe-toho@umin.org. 2. Department of Radiology, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. 3. Department of Radiation Oncology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. 4. Department of Radiology, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Department of Radiation Oncology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.
Abstract
AIM: The current study investigated outcomes and prognostic factors of pulmonary oligometastases at two Institutions. PATIENTS AND METHODS: SBRT (stereotactic body radiotherapy) as performed for pulmonary oligometastases from January 2004 to April 2014, and patients with a biologically effective dose (BED10) ≥ 75 Gy were registered in the study. Control of the primary tumor was not a criterion: we included both oligo-recurrence and sync-oligometastases. RESULTS: A total of 34 patients were enrolled in the study. The median overall survival was 20 months (range=1-119 months) and the 2-year overall survival rate was 65.7% [95% confidence interval (CI)=48.3-83.1%]. The two-year local control rate was 79.1% (95% CI=62.4-95.8%). Stratified by oligo status, the 2-year overall survival rate of the oligo-recurrence group was 68.5% (95% CI=50.3-86.7%), while that of the group with sync-oligometastases was 50.0% (95% CI=1.0-99.0%). These rates were significantly different (p=0.037). No grade 5 early- or late-adverse events were recognized in the current study. CONCLUSION: SBRT for pulmonary oligometastases achieved good results and there was no serious adverse event. The oligo-recurrence group, in particular, achieved fairly good results. Copyright
AIM: The current study investigated outcomes and prognostic factors of pulmonary oligometastases at two Institutions. PATIENTS AND METHODS: SBRT (stereotactic body radiotherapy) as performed for pulmonary oligometastases from January 2004 to April 2014, and patients with a biologically effective dose (BED10) ≥ 75 Gy were registered in the study. Control of the primary tumor was not a criterion: we included both oligo-recurrence and sync-oligometastases. RESULTS: A total of 34 patients were enrolled in the study. The median overall survival was 20 months (range=1-119 months) and the 2-year overall survival rate was 65.7% [95% confidence interval (CI)=48.3-83.1%]. The two-year local control rate was 79.1% (95% CI=62.4-95.8%). Stratified by oligo status, the 2-year overall survival rate of the oligo-recurrence group was 68.5% (95% CI=50.3-86.7%), while that of the group with sync-oligometastases was 50.0% (95% CI=1.0-99.0%). These rates were significantly different (p=0.037). No grade 5 early- or late-adverse events were recognized in the current study. CONCLUSION: SBRT for pulmonary oligometastases achieved good results and there was no serious adverse event. The oligo-recurrence group, in particular, achieved fairly good results. Copyright
Authors: Christopher Cao; Daniel Wang; David H Tian; Ashley Wilson-Smith; James Huang; Andreas Rimner Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: N Andratschke; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; M Guckenberger; G Hildebrandt; R J Klement; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; D Habermehl Journal: BMC Cancer Date: 2018-03-13 Impact factor: 4.430
Authors: Patrick Berkovic; Akos Gulyban; Gilles Defraene; Laurie Swenen; David Dechambre; Paul Viet Nguyen; Nicolas Jansen; Carole Mievis; Pierre Lovinfosse; Levente Janvary; Maarten Lambrecht; Gert De Meerleer Journal: BMC Cancer Date: 2020-05-08 Impact factor: 4.430